Company News

Share this article:
Merck struck a licensing deal with Portola Pharmaceuticals for betrixaban, an experimental anti-blood clotting drug.  According to an AP report, Merck will pay Portola $50 million initially, and a possible total of $470 million if certain goals are met.

Pfizer will appeal the Canadian Federal Court's decision that deemed a patent for Norvasc invalid. The civil action was brought by Ratiopharm, a generics manufacturer. Ratiopharm was granted permission to sell a generic version of the hypertension drug, based on the decision.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.